Bayer Unveils Groundbreaking Pediatric Data for Investigational Low-Dose MRI Contrast Agent Gadoquatrane at RSNA 2025 Radiological Society of North America in Chicago, Bayer announced compelling new findings from the QUANTI…
Johnson & Johnson and Naomi Watts Urge Women Over 40 to Embrace Eye Exams as a Foundational Act of Self-Care Johnson & Johnson Vision—a global leader in eye health—has joined…
Lilly and Indiana University Forge Historic $40 Million Partnership to Revolutionize Clinical Trials and Expand Access to Cutting-Edge Therapies for Hoosiers Eli Lilly and Company and Indiana University (IU) have…
ICON Survey Exposes Escalating Delays in Clinical Trial Startups—Calls for Human-Centred Site Activation Solutions biotechnology, artificial intelligence, and precision medicine, the clinical trial landscape should be accelerating. Yet, a new…
Zoetis Unveils Strategic Vision for the Future of Animal Health at Innovation Webcast, Highlighting Robust R&D Pipeline and Multi-Billion-Dollar Growth Opportunities Zoetis Inc. the global leader in animal health, hosted…
Bayer Launches Pivotal Phase III SUNFLOWER Trial to Evaluate Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Bayer, a global pioneer in women’s healthcare, has officially initiated SUNFLOWER (Study of…
Aetna Medicaid Deepens Commitment to Ending Hunger with $500,000 Investment in Community Food Organizations Nationwide In a powerful demonstration of its ongoing dedication to community health and well-being, Aetna Medicaid—part…
FDA Grants Priority Review to AstraZeneca’s Baxdrostat for Hard-to-Control Hypertension—A Potential First-in-Class Therapy In a significant milestone for cardiovascular innovation, the U.S. Food and Drug Administration (FDA) has accepted AstraZeneca’s…
Roche Launches Groundbreaking 15-Minute Point-of-Care Test for Whooping Cough and Other Bordetella Infections, Receiving FDA Clearance, CLIA Waiver, and CE Mark Roche has announced U.S. Food and Drug Administration (FDA)…
SCRI Unveils Groundbreaking Blood Cancer and Blood Disorder Research Through 100 Abstracts at 2025 ASH Annual Meeting In a historic showing that underscores its growing prominence in hematology research, the…
Johnson & Johnson Secures European Commission Approval for IMAAVY® (nipocalimab)—A Groundbreaking FcRn Blocker for Generalised Myasthenia Gravis In a landmark development for the treatment of generalized myasthenia gravis (gMG), Johnson…
Strand Therapeutics Strengthens Strategic Leadership with Appointment of Industry Veteran Jeb Keiper to Board of Directors Strand Therapeutics, a pioneering biotechnology company at the forefront of programmable mRNA therapeutics, has…
